Results 141 to 150 of about 12,210 (151)

Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab

Eye, 2011
Carsten H Meyer, Holz F G
exaly  

Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo

Experimental Eye Research, 2007
Jihong Yang, Valerie Quarmby, Mauricio Maia   +2 more
exaly  

Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population Approach

2013
Tong Lu, Lisa Tuomi, Steve Eppler
exaly  

Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab

Graefe's Archive for Clinical and Experimental Ophthalmology, 2015
Ying Zhou, Yan-Rong Jiang, Yujing Bai
exaly  

Ranibizumab for the treatment of neovascular age-related macular degeneration: A review

Clinical Therapeutics, 2007
Helen Kourlas
exaly  

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology, 2019
Peter A Campochiaro, Dennis M Marcus, Carl C Awh   +2 more
exaly  

Ranibizumab

Reactions Weekly, 2016
openaire   +1 more source

Ranibizumab

Reactions Weekly
openaire   +2 more sources

Comparison of Bevacizumab, Ranibizumab, and Pegaptanib In Vitro: Efficiency and Possible Additional Pathways

2008
Alexa Klettner
exaly  

Ranibizumab

Reactions Weekly, 2018
openaire   +2 more sources